» Articles » PMID: 20043206

Factors Influencing the Association Between CYP17 T34C Polymorphism and the Risk of Breast Cancer: Meta-regression and Subgroup Analysis

Overview
Specialty Oncology
Date 2010 Jan 1
PMID 20043206
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

A number of studies have been investigated the association between CYP17 T34C polymorphism and the risk of breast cancer; the results of these studies are inconsistent, however. This fact implies that the effect of CYP17 T34C polymorphism on susceptibility to breast cancer may be modified by other risk factors. In order to provide a more definitive conclusion, a full meta-analysis combining and summarizing 24 studies was first performed. Both traditional method and Bayesian approach were applied. Odds ratio was estimated using a dominant mode of inheritance after a biological justification for the choice of genetic model. The results of homogeneity analysis (H = 1.16, I (2) = 25.4%, and P = 0.127) suggested the presence of heterogeneity across the studies. Thus, random effects models simulated by the DerSimonian-Laird method were employed. The capability of a Bayesian approach was highlighted in the estimation of a pooled odds ratio and 95% confidence interval. The results of meta-analysis (OR = 1.001, CI = 0.832-1.208) suggest no significant association in the combined populations. Furthermore, Bayesian meta-regression and subgroup analysis were conducted to investigate the sources of heterogeneity. The risk factors evaluated in the study were menopausal status, ethnicity, age at menarche, age at first birth, parity, use of oral contraceptives, body mass index (BMI), and use of hormone repair therapy (HRT). After these population stratifications, there was evidence indicating that a possible impact of menopausal status, age at menarche, and BMI on the association between CYP17 T34C polymorphism and the risk of breast cancer.

Citing Articles

CYP17 T/C (rs74357) gene polymorphism contributes to polycystic ovary syndrome susceptibility: evidence from a meta-analysis.

Liu X, Xu M, Qian M, Yang L Endocr Connect. 2021; 10(12):R305-R316.

PMID: 34788226 PMC: 8679930. DOI: 10.1530/EC-21-0327.


Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk.

Rizzolo P, Silvestri V, Valentini V, Zelli V, Bucalo A, Zanna I Endocr Connect. 2019; 8(8):1224-1229.

PMID: 31336362 PMC: 6733362. DOI: 10.1530/EC-19-0225.


Association between CYP17 T-34C rs743572 and breast cancer risk.

Sun J, Zhang H, Gao M, Tang Z, Guo D, Zhang X Oncotarget. 2018; 9(3):4200-4213.

PMID: 29423115 PMC: 5790532. DOI: 10.18632/oncotarget.23688.


Review of the Gene-Environment Interaction Literature in Cancer: What Do We Know?.

Simonds N, Ghazarian A, Pimentel C, Schully S, Ellison G, Gillanders E Genet Epidemiol. 2016; 40(5):356-65.

PMID: 27061572 PMC: 4911236. DOI: 10.1002/gepi.21967.


A Single Nucleotide Polymorphism near the CYP17A1 Gene Is Associated with Left Ventricular Mass in Hypertensive Patients under Pharmacotherapy.

Huber M, Lezius S, Reibis R, Treszl A, Kujawinska D, Jakob S Int J Mol Sci. 2015; 16(8):17456-68.

PMID: 26263970 PMC: 4581202. DOI: 10.3390/ijms160817456.